Screener
Jazz Pharmaceuticals JAZZ Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Research and development | 196.0 | 180.7 |
| Intangible asset amortization | 172.3 | 154.4 |
| Gain on sale of priority review voucher | (122.8) | — |
| Total operating expenses | 732.3 | 953.7 |
| Income (loss) from operations | 336.6 | (55.9) |
| Interest expense, net | (39.9) | (53.7) |
| Foreign exchange gain (loss) | 2.5 | (0.2) |
| Income (loss) before income tax expense (benefit) and equity in loss of investees | 299.2 | (109.8) |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's total costs & expenses?
- Jazz Pharmaceuticals (JAZZ) reported total costs & expenses of $732.3M in Q1 2026.
- How has Jazz Pharmaceuticals's total costs & expenses changed year-over-year?
- Jazz Pharmaceuticals's total costs & expenses decreased by 23.2% year-over-year, from $953.7M to $732.3M.
- What is the long-term trend for Jazz Pharmaceuticals's total costs & expenses?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's total costs & expenses has grown at a 12.6% compound annual growth rate (CAGR), from $2.92B to $4.7B.
- What does total costs & expenses mean?
- The aggregate of all operating and non-operating costs, including cost of sales, R&D, SG&A, and other charges incurred during the reporting period. This metric represents the total financial burden required to sustain the company's operations.
Ask your AI about Jazz Pharmaceuticals's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude